Table 2 Treatment outcomes for patients based on breast cancer subtypes
Triple-negative breast cancer | ER-positive/HER2-negative breast cancer | HER2-positive breast cancer | Total/overall | |
|---|---|---|---|---|
Median overall survival (95% CI) | 8.5 months (4.9–12.2) | 8.7 months (3.9- 13.5) | 8.7 months (7.3–10.2) | 8.7 months (7.6- 9.8) |
Median time to progression (95% CI) | 8.8 weeks (5.8–11.8) | 6.5 weeks (5.7–7.3) | 7.4 weeks (6.5–8.3) | 7.0 weeks (6.4–7.5) |
RECIST response rate | 6/26 (23.0%) | 0/23 (0%) | 2/21(9.5%) | 8/70 (11.4%) |
CBR (PR+SD) at 4 months | 8/26 (30.7%) | 2/23 (8.7%) | 4/21 (19%) | 14/70 (20%) |
Type of phase 1 trial | ||||
First in human | 20 | 22 | 19 | 61 |
Chemotherapy combination | 6 | 1 | 2 | 9 |
Target of phase 1 trial | ||||
DNA repair (PARP) | 12 | 4 | 1 | 17 |
AKT/PI3K/ MTOR pathways | 5 | 3 | 2 | 10 |
Hormone synthesis | 0 | 8 | 4 | 12 |
Growth factor receptor pathways | 1 | 0 | 3 | 4 |
Anti-angiogenesis | 2 | 0 | 3 | 5 |
Cell cycle and apoptosis | 3 | 0 | 1 | 4 |
Chromatin remodelling and antisense | 0 | 5 | 1 | 6 |
Protein turnover (HSP90) | 0 | 2 | 3 | 5 |
Other signalling pathways (Ras, SRC, IGF, c-met) | 3 | 1 | 3 | 7 |
Total | 26 | 23 | 21 | 70 |
